JP2017522304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522304A5 JP2017522304A5 JP2017500911A JP2017500911A JP2017522304A5 JP 2017522304 A5 JP2017522304 A5 JP 2017522304A5 JP 2017500911 A JP2017500911 A JP 2017500911A JP 2017500911 A JP2017500911 A JP 2017500911A JP 2017522304 A5 JP2017522304 A5 JP 2017522304A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- group
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 96
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 125000001072 heteroaryl group Chemical group 0.000 claims description 54
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 125000004429 atom Chemical group 0.000 claims description 38
- -1 R 21 Chemical compound 0.000 claims description 35
- 125000001188 haloalkyl group Chemical group 0.000 claims description 33
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000003107 substituted aryl group Chemical group 0.000 claims description 15
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 14
- 229910052805 deuterium Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 9
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000037317 transdermal delivery Effects 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000002550 vasoactive agent Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 150000008143 steroidal glycosides Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical class C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 7
- 125000002877 alkyl aryl group Chemical group 0.000 description 6
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 6
- 0 C*CC1CCCC1 Chemical compound C*CC1CCCC1 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- 150000001602 bicycloalkyls Chemical group 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000005347 halocycloalkyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/046920 WO2016010538A1 (en) | 2014-07-16 | 2014-07-16 | Treprostinil derivative compounds and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019134245A Division JP2020011957A (ja) | 2019-07-22 | 2019-07-22 | トレプロスチニル誘導体化合物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522304A JP2017522304A (ja) | 2017-08-10 |
| JP2017522304A5 true JP2017522304A5 (enExample) | 2017-09-21 |
| JP6561109B2 JP6561109B2 (ja) | 2019-08-14 |
Family
ID=51298985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500911A Active JP6561109B2 (ja) | 2014-07-16 | 2014-07-16 | トレプロスチニル誘導体化合物およびその使用方法 |
Country Status (3)
| Country | Link |
|---|---|
| EP (2) | EP3828160A1 (enExample) |
| JP (1) | JP6561109B2 (enExample) |
| WO (1) | WO2016010538A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| US9371264B2 (en) | 2013-01-11 | 2016-06-21 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| HU231186B1 (hu) | 2014-10-08 | 2021-06-28 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Új eljárás treprostinil és sói előállítására |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| EP3515430A1 (en) * | 2016-09-26 | 2019-07-31 | United Therapeutics Corporation | Treprostinil prodrugs |
| KR20250002687A (ko) | 2022-04-29 | 2025-01-07 | 자오커 파마슈티컬 (광저우) 컴퍼니., 리미티드 | 트레프로스티닐 소프트 미스트 흡입제 |
| CN115894240B9 (zh) * | 2022-10-14 | 2026-03-13 | 广州楷石医药有限公司 | 曲前列尼尔的前体药物及其应用 |
| CN115448839B (zh) * | 2022-10-14 | 2025-02-14 | 广州楷石医药有限公司 | 一种曲前列尼尔的前体药物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4144317A (en) | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
| US4262003A (en) | 1975-12-08 | 1981-04-14 | Alza Corporation | Method and therapeutic system for administering scopolamine transdermally |
| US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
| US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| IN184589B (enExample) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| US6242482B1 (en) * | 2000-06-05 | 2001-06-05 | United Therapeutics Corporation | Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure |
| US20030108512A1 (en) * | 2001-12-10 | 2003-06-12 | Robert Shorr | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer |
| WO2005007081A2 (en) | 2003-05-22 | 2005-01-27 | United Therapeutics Corporation | Compounds and methods for delivery of prostacyclin analogs |
| EA201070127A1 (ru) | 2007-07-11 | 2010-08-30 | Лексикон Фармасьютикалз , Инк. | Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления |
| EP2576492B1 (en) * | 2010-06-03 | 2017-09-20 | United Therapeutics Corporation | Treprostinil production |
| JP6092867B2 (ja) * | 2011-08-12 | 2017-03-08 | アセンディス ファーマ エー／エス | 担体連結しているトレプロスチニルプロドラッグ |
| US9371264B2 (en) * | 2013-01-11 | 2016-06-21 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
-
2014
- 2014-07-16 EP EP20202064.0A patent/EP3828160A1/en active Pending
- 2014-07-16 JP JP2017500911A patent/JP6561109B2/ja active Active
- 2014-07-16 EP EP14748380.4A patent/EP3169660A1/en not_active Withdrawn
- 2014-07-16 WO PCT/US2014/046920 patent/WO2016010538A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522304A5 (enExample) | ||
| JP2016510323A5 (enExample) | ||
| JP2020169171A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP2013010792A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2015509983A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| WO2009082818A8 (en) | Novel c-21-keto lupane derivatives preparation and use thereof | |
| CN107205994A (zh) | 脂肪酸半胱胺缀合物和它们作为自噬的活化剂的用途 | |
| JP2018515495A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| JP2017508816A5 (enExample) | ||
| JP2013519653A5 (enExample) | ||
| JP2011500621A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| JP7159440B2 (ja) | ジカチオン化合物及びその製造方法と使用 | |
| JP2020500866A5 (enExample) |